Clinical Trial Update: Clinical Endpoint Study of Ivermectin 0.5% Lotion [Phase 3]

View source ↗

Summary

Phase 3 clinical endpoint study of ivermectin 0.5% lotion for head lice has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head Lice

Drugs mentioned

• ivermectin 0.5% lotion (ivermectin)

Snippet

Sponsor: Actavis Inc. | Conditions: Head Lice | Phase 3 | Status: COMPLETED | Results posted: 2019-12-20